



Technical Report No. 71

Emerging Methods for Virus Detection

Currently in preview, click buy full version



PDA Emerging Methods for Virus Detection Technical Report Team

Authors

Arifa S. Khan, Ph.D., U.S. FDA/CBER, Co-Leader

Kathryn E. King, Ph.D., U.S. FDA/CDER, Co-Leader

Kerstin Brack, Ph.D., Charles River Laboratories

Jean-Pol Cassart, Ph.D., GSK Vaccines

Charles Chiu, MD, Ph.D., University of California, San Francisco

Houman Dehghani, Ph.D., Amgen

Paul Duncan, Ph.D., Merck & Co., Inc.

Crystal Jaing, Ph.D., Lawrence Livermore National Lab

John Kolman, Ph.D., BioReliance

David Munroe, Ph.D., SAIC-Frederick

Adam Palermo, Ph.D., Genzyme

Mark Plavsic, Ph.D., Genzyme

Rangarajan Sampath, Ph.D., Abbott

Tom Slezak, Lawrence Livermore National Lab

Garry Takle, Ph.D., Merck & Co., Inc.

Lanyn P. Taliaferro, Ph.D., U.S. FDA/CBER

Emiliano Toso, Ph.D., EMD Serono

Dominick Vacante, Ph.D., Janssen R&D

Hannelore Willkommen, Ph.D., RBS Consulting

Contributors

Laura Barberis, Ph.D., EMD Serono

Martin Wisner, Ph.D., BioReliance

DISCLAIMER: The findings and conclusions in this article should not be construed to represent the U.S. Food and Drug Administration's views or policy. The content and views expressed in this technical report are those of the individual authors and are not necessarily views of the organization, regulatory authority, or governmental agency they represent. The mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. government.

Emerging Methods for Virus Detection

Technical Report No. 71

ISBN: 1-80-939459-77-9

© 2015 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1	6.2 Benefits and Limitations	16
1.1 Purpose	2	6.3 Biopharmaceutical Applications	17
1.2 Scope	2	6.3.1 General Microorganism Detection	17
2.0 GLOSSARY OF TERMS	3	6.3.2 Parvovirus Detection.....	18
3.0 CONVENTIONAL VIRUS DETECTION METHODS ..	4	6.3.3 Unknown Virus Detection	20
3.1 Assays for Routine Viral Testing	4	6.3.4 General Virus Detection	21
3.1.1 In Vivo Assays	4	7.0 MASSIVELY PARALLEL SEQUENCING	23
3.1.1.1 Benefits and Limitations	5	7.1 Description of the Method.....	23
3.1.2 Cell-Based In Vitro Assays for General		7.1.1 Sample Preparation	23
Adventitious Viruses.....	5	7.1.2 Sequencing Platforms.....	24
3.1.2.1 Benefits and Limitations	5	7.1.3 Data Analysis	25
3.1.3 Cell-Based In Vitro Assays for Detection		7.2 Benefits and Limitations	27
of Specific Animal Viruses	6	7.3 Biopharmaceutical Applications	28
3.1.3.1 Benefits and Limitations	6	7.3.1 Case Studies.....	29
3.1.4 Transmission Electron Microscopy	6	8.0 BROAD-SPECTRUM MICROBIAL DETECTION	
3.1.4.1 Benefits and Limitations	6	MICROARRAYS	31
3.1.5 Retrovirus Detection Assays	7	8.1 Description of the Method.....	31
3.1.6 PCR Assays.....	8	8.1.1 Overview of Different Pathogen Detection	
3.1.6.1 Benefits and Limitations	9	Microarrays	32
3.2 Additional Assays for Novel Cell Substrates.....	9	8.1.1.1 ViroChip.....	32
4.0 THE NEED FOR NEW TECHNOLOGIES		8.1.1.2 GreeneChip.....	32
FOR VIRUS DETECTION	10	8.1.1.3 Lawrence Livermore Microbial	
5.0 DEGENERATE AND CONSENSUS PCR ASSAYS ..	11	Detection Array (LLMDA)	33
5.1 Description of the Method	11	8.2 Benefits and Limitations of Microarrays	34
5.1.1 Consensus Sequence PCR Assays	12	8.3 Biopharmaceutical Applications	35
5.1.2 Universal Amplification.....	12	9.0 GENERAL CONSIDERATIONS AND SUMMARY ...36	
5.2 Benefits and Limitations	13	9.1 Particular Considerations for Sample Types	
5.3 Biopharmaceutical Applications	13	and Preparation	38
6.0 BROAD-RANGE PCR WITH ELECTROSPRAY		9.2 Considerations for Bioinformatics.....	38
IONIZATION MASS SPECTROMETRY		10.0 CONCLUSION	40
(PCR/ESI-MS)	15	11.0 REFERENCES	41
6.1 Description of Method.....	15		
6.1.1 Sample Preparation	16		
6.1.2 Broad Virus Assays	16		
6.1.3 Data Analysis	16		

FIGURES AND TABLES INDEX

Table 1.0-1	Viruses Detected in Biological Product Manufacturing 2	Table 6.3.3-2	Base-Composition Signature Analysis of BTV Amplicons..... 21
Table 3.1.5-1	Retrovirus Detection Assays..... 8	Table 6.3.4-1	Detection of Spiked Known Viruses and Endogenous Viruses Using Broad Viral Detection Panels..... 22
Table 5.2-1	Benefits and Limitations of Degenerate PCR Assays 13	Table 7.0-1	Examples of MPS Platforms 23
Figure 6.1-1	Schematic of the PCR/ESI-MS Approach for Pathogen Detection 15	Table 7.1.2-1	Characteristics of Available MPS Platforms 24
Table 6.2-1	Benefits and Limitations of PCR/ESI-MS..... 17	Table 7.1.2-2	Impact of Sequence Length on BLASTn Output 25
Table 6.3.1-1	PCR/ESI-MS Detection and Identification of Challenge Organisms 18	Table 7.2-1	Benefits and Limitations of MPS..... 28
Figure 6.3.2-1	Detection of MMV Using a Parvovirus Kit..... 19	Figure 7.3.1-1	Relationship of Virus Concentration to Read Count 30
Figure 6.3.2-2	Detection of MMV in Infected CHO Cell Culture over the Course of 12 Days Using an MMV-Specific Real-Time PCR and the Biosensor System..... 20	Table 8.2-1	Benefits and Limitations of Microarrays 35
Table 6.3.3-1	Detection of Bluetongue Virus–Like (BTV) Sequences Using Base-Composition Signatures in Four Infected Cell Lines 21	Table 9.0-1	Summary of Adventitious Virus Detection Methods 36

1.0 Introduction

The potential for extraneous microbial agents to be present in biological medicines was recognized as early as the late nineteenth century, resulting in enactment of the 1902 Biologics Control Act in the United States. More rigorous federal regulations for the development and testing of biological products were passed following the well-publicized discovery of SV40 in poliovirus vaccines used in the 1950s (1,2).

International and national government organizations and regulatory agencies provide both recommendations and legal requirements, or codes, to manufacturers for developing a suitable testing design to ensure the safety and purity of their products. In the United States, the Food and Drug Administration (FDA) publishes recommendations through Guidance for Industry and Points to Consider documents as well as legal requirements through the Code of Federal Regulations (CFR) which defines and describes testing of biological medicinal products. In the European Union, the European Pharmacopoeia (PhEur) and the European Medicines Agency (EMA), together with the various national governing bodies, publish documents describing required testing practices and expectations. Throughout the rest of the world, attempts have been made to harmonize expectations and testing paradigms, with the goal of assuring that products do not contain infectious adventitious agents. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has made significant progress in establishing worldwide, harmonized best practices for approaches to adventitious agent detection and risk mitigation (3,4). Additionally, the World Health Organization (WHO) has updated TRS 878, Annex 2, *Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell Banks* (5).

Despite the required virus testing of biologic drugs, rare cases of introduction of adventitious agents into a production stream or product have been reported (Table 1.0-1). Of note, the majority of these contamination events were traced to raw materials used during manufacturing. Such events have served to refocus the effort to establish more effective surveillance programs, mitigation strategies, and use methods for enhancing adventitious agent detection. Although current methods for detecting adventitious viruses have provided a generally good safety record of biological medicines over the years, these methods may not detect latent or occult viruses, novel viruses, and even some known viruses. Emerging nucleic based methods have demonstrated potential to fill these gaps for virus detection.